Lidocaine HCl structure
|
Common Name | Lidocaine HCl | ||
---|---|---|---|---|
CAS Number | 6108-05-0 | Molecular Weight | 288.814 | |
Density | N/A | Boiling Point | 350.8ºC at 760 mmHg | |
Molecular Formula | C14H25ClN2O2 | Melting Point | 68.5ºC | |
MSDS | Chinese USA | Flash Point | 166ºC | |
Symbol |
GHS06 |
Signal Word | Danger |
Use of Lidocaine HClLidocaine hydrochloride hydrate (Lignocaine hydrochloride hydrate) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia[1][2]. |
Name | lidocaine hydrochloride monohydrate |
---|---|
Synonym | More Synonyms |
Description | Lidocaine hydrochloride hydrate (Lignocaine hydrochloride hydrate) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia[1][2]. |
---|---|
Related Catalog | |
Target |
ERK NF-κB MEK |
In Vitro | Lidocaine (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation[2]. Lidocaine (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours[2]. Lidocaine (10 nM; 48 hours) increases significantly the apoptotic cell rate[2]. Lidocaine (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly[2]. Cell Proliferation Assay[2] Cell Line: The human gastric cancer cell line MKN45 Concentration: 10 nM Incubation Time: 48 hours Result: Decreased significantly cell proliferation. Cell Viability Assay[2] Cell Line: The human gastric cancer cell line MKN45 Concentration: 1, 5 and 10 nM Incubation Time: 24, 48, 72 hours Result: Inhibited MKN45 cell viability. Apoptosis Analysis[2] Cell Line: The human gastric cancer cell line MKN45 Concentration: 10 nM Incubation Time: 48 hours Result: Increased significantly the apoptotic cell rate. Western Blot Analysis[2] Cell Line: The human gastric cancer cell line MKN45 Concentration: 10 nM Incubation Time: 48 hours Result: Down-regulated Cyclin D1 and up-regulated p21 expression significantly. |
In Vivo | Lidocaine (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block[3]. |
References |
Boiling Point | 350.8ºC at 760 mmHg |
---|---|
Melting Point | 68.5ºC |
Molecular Formula | C14H25ClN2O2 |
Molecular Weight | 288.814 |
Flash Point | 166ºC |
Exact Mass | 288.160461 |
PSA | 41.57000 |
LogP | 3.39440 |
Water Solubility | H2O: soluble |
Section 1. Chemical Product and Company Identification Lidocaine Hydrochloride monohydrate Common Name/ Trade Name Lidocaine Hydrochloride monohydrate Section 4. First Aid Measures Eye ContactCheck for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for
at least 15 minutes. Cold water may be used. Get medical attention if irritation occurs. Skin ContactWash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops. Cold water may be used. Serious Skin ContactNot available. InhalationIf inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention. Serious InhalationNot available. IngestionDo NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar, tie, belt or waistband. Serious IngestionNot available. Section 5. Fire and Explosion Data Flammability of the Product May be combustible at high temperature. Auto-Ignition Temperature Not available. Flash PointsNot available. Flammable LimitsNot available. Products of CombustionThese products are carbon oxides (CO, CO2), nitrogen oxides (NO, NO2...), halogenated compounds. Fire Hazards in Presence of Slightly flammable to flammable in presence of heat. Various Substances Explosion Hazards in Presence Risks of explosion of the product in presence of mechanical impact: Not available. of Various SubstancesRisks of explosion of the product in presence of static discharge: Not available. Fire Fighting MediaSMALL FIRE: Use DRY chemical powder. and InstructionsLARGE FIRE: Use water spray, fog or foam. Do not use water jet. Special Remarks onAs with most organic solids, fire is possible at elevated temperatures Fire Hazards Special Remarks on Explosion Fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential Hazardsdust explosion hazard. Section 6. Accidental Release Measures Small SpillUse appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on the contaminated surface and dispose of according to local and regional authority requirements. Large SpillUse a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the contaminated surface and allow to evacuate through the sanitary system. Section 7. Handling and Storage Keep away from heat. Keep away from sources of ignition. Ground all equipment containing material. Do not Precautions ingest. Do not breathe dust. Wear suitable protective clothing. If ingested, seek medical advice immediately and show the container or the label. Keep away from incompatibles such as oxidizing agents. StorageKeep container tightly closed. Keep container in a cool, well-ventilated area. Lidocaine Hydrochloride monohydrate Section 8. Exposure Controls/Personal Protection Engineering ControlsUse process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants below the exposure limit. Personal ProtectionSafety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves. Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be a Large Spillused to avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this product. Exposure LimitsNot available. Section 9. Physical and Chemical Properties Physical state and appearance Solid. (crystalline powder.)OdorOdorless. TasteNot available. Molecular Weight288.81 g/mole ColorWhite. pH (1% soln/water)Not available. Not available. Boiling Point Melting Point74°C (165.2°F) Critical TemperatureNot available. Specific GravityNot available. Vapor PressureNot applicable. Vapor DensityNot available. VolatilityNot available. Not available. Odor Threshold Water/Oil Dist. Coeff.Not available. Ionicity (in Water)Not available. Dispersion PropertiesSee solubility in water. SolubilityEasily soluble in cold water. Insoluble in diethyl ether. Soluble in benzene, ethanol, chloroform Section 10. Stability and Reactivity Data The product is stable. Stability Instability TemperatureNot available. Excess heat, incompatible materials Conditions of Instability Incompatibility with variousReactive with oxidizing agents. substances CorrosivityNon-corrosive in presence of glass. Special Remarks onNot available. Reactivity Special Remarks onNot available. Corrosivity PolymerizationWill not occur. Lidocaine Hydrochloride monohydrate Section 11. Toxicological Information Routes of EntryAbsorbed through skin. Inhalation. Ingestion. Toxicity to AnimalsAcute oral toxicity (LD50): 292 mg/kg [Mouse]. Chronic Effects on HumansCauses damage to the following organs: the nervous system. May cause damage to the following organs: cardiovascular system, central nervous system (CNS). Other Toxic Effects onHazardous in case of ingestion. HumansSlightly hazardous in case of skin contact (irritant), of inhalation. Special Remarks onNot available. Toxicity to Animals Special Remarks on May cause adverse reproductive effects and birth defects (teratogenic) based on animal test data Chronic Effects on Humans Special Remarks on otherAute Potential Health Effects: Toxic Effects on HumansSkin: May cause skin irritation and numbness (anesthetic effect). When applied to the skin, it produces an anesthetic effect by blocking the signals at the nerve endings of the skin. when compounded with an ointment and applied topically, It may be absorbed by the skin cause systemic effects similar to that of ingestion. Eyes: May cause eye irritation and numbness. Inhalation: Dust may cause respiratory tract irritation and numbness. Ingestion: Harmful of swallowed. May cause abdominal discomfort, nausea, vomiting. May affect behavior/central nervous system (convulsions/seizures, drowsiness, lightheadedness, dizziness, confusion, disorientation, muscle twitching or trembling, somnolence, unusual excitement, unusual tiredness or weakness, nervousness, restlessness), cardiovascular system (hypotension, change in heart rate with possibe cardiac arrest). May also cause shortness of breath or trouble breathing, ringing or buzzing in the ears, feeling hot, cold or numb, increased sweating, blurred or double vision. Chronic Potential Health Effects: Skin: May cause allergic skin reaction with rash, hives, swelling, or abnormal sensation at the site of application. Ingestion/Inhalation: It is rare, but it may cause allergic reaction with cough, difficulty swallowing or tongue swelling, dizziness or fainting, hives or swelling of the eyelids, face or lips; itching or skin rash, stuffy nose, chest tightness, shortness of breath, trouble breathing or wheezing. Medical Conditions Aggravated by Exposure: Hypersensitivity to material; respiratory depression; existing cardiac conditions; broken or inflammed skin, burns, or open wounds at the place of application. More can be absorbed into the body quickly, which increases the chance of side effects; Liver disease (severe). The risk of side effects may be increased because of the slower removal of lidocaine from the body. Section 12. Ecological Information EcotoxicityNot available. BOD5 and CODNot available. Possibly hazardous short term degradation products are not likely. However, long term degradation products Products of Biodegradation may arise. Toxicity of the ProductsThe products of degradation are more toxic. of Biodegradation Not available. Special Remarks on the Products of Biodegradation Section 13. Disposal Considerations Waste must be disposed of in accordance with federal, state and local environmental Waste Disposal control regulations. Lidocaine Hydrochloride monohydrate Section 14. Transport Information DOT ClassificationNot a DOT controlled material (United States). Not applicable. Identification Not applicable. Special Provisions for Transport DOT (Pictograms) Section 15. Other Regulatory Information and Pictograms No products were found. It is not listed on the TSCA inventory because it is a hydrate. Federal and State Regulations California prop. 65: This product contains the following ingredients for which the State of California has California found to cause cancer which would require a warning under the statute: No products were found. Proposition 65 Warnings California prop. 65: This product contains the following ingredients for which the State of California has found to cause birth defects which would require a warning under the statute: No products were found. Other RegulationsOSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200). EINECS: This product is not on the European Inventory of Existing Commercial Chemical Substances. Canada: Not listed on Canadian Domestic Substance List (DSL) or Canadian Non- Domestic Substance List (NDSL). China: Not listed on National Inventory. Japan: Not listed on National Inventory (ENCS). Korea: Not listed on National Inventory (KECI). Philippines: Not listed on National Inventory (PICCS). Australia: Not listed on AICS. WHMIS (Canada) Not available under WHMIS (Canada). Other Classifications DSCL (EEC)R22- Harmful if swallowed.S36- Wear suitable protective clothing. S46- If swallowed, seek medical advice immediately and show this container or label. Health Hazard HMIS (U.S.A.)2 National Fire Protection 1 Flammability 1 Association (U.S.A.) Fire Hazard 2 0 Reactivity Health Reactivity 0 Specific hazard Personal Protection E WHMIS (Canada) (Pictograms) DSCL (Europe) (Pictograms) TDG (Canada) (Pictograms) Lidocaine Hydrochloride monohydrate ADR (Europe) (Pictograms) Protective Equipment Gloves. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. SECTION 16 - ADDITIONAL INFORMATION N/A |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
Hazard Codes | Xn: Harmful; |
Risk Phrases | 22 |
Safety Phrases | 36 |
RIDADR | UN 2811 6 |
WGK Germany | 3 |
RTECS | AN7700000 |
HS Code | 2924299090 |
HS Code | 2924299090 |
---|---|
Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Development and in vitro evaluation of a buccal drug delivery system based on preactivated thiolated pectin.
Drug Dev. Ind. Pharm. 40(11) , 1530-7, (2014) The aim of this study was to evaluate the potential of preactivated thiolated pectin (Pec-Cys-MNA) for buccal drug delivery. Therefore, a gel formulation containing this novel polymer and the model dr... |
|
Evaluation of regional limb perfusion with chloramphenicol using the saphenous or cephalic vein in standing horses.
J. Vet. Pharmacol. Ther. 38(1) , 35-40, (2015) Regional limb perfusion (RLP) significantly decreases morbidity and mortality associated with distal limb injuries in horses. There is an urgent need for finding additional effective antimicrobial dru... |
|
Intravenous lidocaine decreases tumor necrosis factor alpha expression both locally and systemically in pigs undergoing lung resection surgery.
Anesth. Analg. 119(4) , 815-28, (2014) Lung resection surgery is associated with an inflammatory reaction. The use of 1-lung ventilation (OLV) seems to increase the likelihood of this reaction. Different prophylactic and therapeutic measur... |
2-(diéthylamino)-N-(2,6-diméthylphényl)acétamide chlorhydrate hydrate |
Xyloneural |
MFCD00150329 |
2-(Diethylamino)-2',6'-acetoxylidide Hydrochloride Hydrate |
Lidocaine Hydrochloride Monohydrate |
Lidocaine hydrochloride anhydrous |
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride hydrate |
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamidhydrochloridhydrat |
Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, hydrochloride, hydrate (1:1:1) |
EINECS 200-803-8 |
Xylocard |
N-(2,6-Dimethylphenyl)-N,N-diethylglycinamide hydrochloride hydrate |
Linocaine hydrochloride |
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide Monohydrochloride Monohydrate |
Lidocaine HCl |